Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
Real-time Quote. Real-time Tradegate - 08/15 07:16:25 pm
80.85 EUR   -3.47%
11:30aBAYER AKTIENGES : Notification and public disclosure of transactions..
08:48aDAVID EINHORN : Bayer Brings No Relief to Einhorn -- WSJ
08/14MONSANTO ROUNDU : legal experts
Analysis summaryMarketScreener Strategies

Ulrich Ebensperger

Financial Analyst
share with twitter share with LinkedIn share with facebook
share via e-mail

Still trending down

Strategy published on 07/11/2018 | 09:17
short sell
Target price hit
Entry price : 93.96€ | Target : 88.05€ | Stop-loss : 100€ | Potential : 6.29%
The trend in the price decline should not be put into question for stocks in Bayer over the coming trading sessions given the current chart pattern.
Investors should open a short trade and target the € 88.05.
  • The company has poor fundamentals for a short-term investment strategy.

  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 88.91 EUR in weekly data.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • The company is in debt and has limited leeway for investment
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2018 39 152 M
EBIT 2018 7 845 M
Net income 2018 4 895 M
Debt 2018 33 029 M
Yield 2018 3,32%
P/E ratio 2018 17,15
P/E ratio 2019 15,06
EV / Sales 2018 2,84x
EV / Sales 2019 2,35x
Capitalization 78 083 M
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Bayer Technical Analysis Chart | MarketScreener
Duration : Period : Week
Bayer Technical Analysis Chart | MarketScreener